SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs about secretarial compliance report

15 May 2025 Evaluate

In compliance with the provisions of Regulation 24A of SEBI LODR Amendment Regulations, 2018, read with SEBI Circular dated February 08, 2019, GlaxoSmithKline Pharmaceuticals has informed that it enclosed Annual Secretarial Compliance Report of the Company for the financial year ended 31st March 2025.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2408.05 -1.80 (-0.07%)
15-Apr-2026 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.40
Dr. Reddys Lab 1215.45
Cipla 1226.35
Zydus Lifesciences 936.20
Lupin 2340.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×